Period4 Dec 2019

Media coverage

1

Media coverage

  • TitleEolas Therapeutics Announce Initiation of a Phase I Clinical Trial for AZD4041, an Orexin-1 Receptor Antagonist for Smoking Cessation.
    Media name/outletPRWeb Newswire
    Country/TerritoryUnited States
    Date4/12/19
    PersonsPaul Kenny